Korro Bio: 10% owner Lynx1 Capital Management LP buys $884,751 stock
Lynx1 Capital Management LP, a 10% owner and director of Korro Bio, Inc., recently purchased $884,751 worth of common stock in the company. The shares were acquired over a few days in late October 2026 at prices ranging from $9.6764 to $12.1061 per share. Lynx1 Capital Management LP's stake in Korro Bio increased as a result. The company's stock saw a 35% increase over the past week, currently trading at $12.02.
Lynx1 Capital Management LP, acting through Lynx1 Master Fund LP, now holds 1,624,789 shares of Korro Bio. This acquisition comes after the company announced the start of a Phase 1/2 clinical trial for KRRO-121, targeting hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy. Both H.C. Wainwright and Raymond James have maintained positive outlooks on Korro Bio, with price targets of $15.00 and $23.00 respectively.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
